If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Trulicity ® (dulaglutide) injection
0.75 mg/0.5 mL, 1.5 mg/0.5 mL
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
TRULICITY® (dulaglutide): QTC Interval
At supratherapeutic doses (4 and 7 mg), dulaglutide does not prolong QTc.
The effect of dulaglutide on cardiac repolarization was thoroughly tested in a QTc study and found that at supratherapeutic doses, dulaglutide 4 mg and dulaglutide 7 mg did not prolong QTc.1
Enclosed Prescribing Information
TRULICITY® (dulaglutide) injection, for subcutaneous use, Lilly
1. Trulicity [package insert]. Indianapolis, IN: Eli Lilly and Company; 2019.
Glossary
QTc = corrected QT interval
Date of Last Review: January 03, 2020
Contact Lilly
Call Us
If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.
Available Mon - Fri, 9am - 8pm ET
